Does the FIGO 2009 Endometrial Cancer Staging System More Accurately Correlate With Clinical Outcome in Different Histologies?

Page, B.R.; Pappas, Lisa M.; Cooke, Ellen W.; Gaffney, David K.

doi:10.1097/igc.0b013e3182412ebd

Cited by 25 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This renewal in the staging system is supported by other studies [8,9,11,14]. Abu-Rustum et al [13] found a survival difference for 1988 stage IA and IB endometrioid carcinomas, but instead of disease specific survival they had overall survival as their end-point.…”

Section: Discussionmentioning

confidence: 74%

“…A European multicenter study recruited patients with endometrioid and nonendometrioid carcinomas to analyze the disease specific survival using FIGO 1988 and 2009 systems [10]. The cause specific survival of patients with nonendometrioid carcinomas was assessed in a register-based study from the United States [11], and a study from Korea compared the overall survival of nonendometrioid carcinomas with that of grade 3 endometrioid carcinomas [12]. Lastly, overall survivals according to the two staging systems were compared in two single institution studies [13,14], one of which sought to describe survival differences for various substages of stage I endometrioid carcinomas [13].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype

et al. 2014

View full text Add to dashboard Cite

ObjectiveThe surgical staging system for endometrial carcinoma developed by International Federation of Gynecology and Obstetrics (FIGO) in 1988 was revised in 2009. Given the importance of continuous validation of the prognostic performance of staging systems, we analyzed the disease specific survival for patients with endometrial carcinoma using FIGO 1988 and 2009 systems. Further, the stage distribution of endometrioid and nonendometrioid carcinomas was studied.MethodsEight hundred twenty-one women with endometrial carcinoma were retrospectively staged using FIGO 1988 and 2009 systems.ResultsFIGO 1988 IC was associated with an inferior survival compared with IA-IB. Survival overlapped for 1988 IA and IB, for 1988 IC and IIA, and for 2009 IB and II. FIGO 2009 IA-II patients with negative peritoneal cytology had a superior survival compared with 1988 IIIA patients with positive cytology only. The survival was similar for 1988 IIIA with positive cytology only and for 2009 IIIA. Cox proportional hazards model recognized grade 3 endometrioid and nonendometrioid histology, tumor spread beyond the uterine corpus and cervix, and positive peritoneal cytology as significant predictors of death. Among 2009 IIIC substages, the proportion of IIIC2 tumors was higher for nonendometrioid than for endometrioid carcinomas (p=0.003).ConclusionStage I with deep myometrial invasion and stage II endometrial carcinoma seem to have similar survival outcomes. Although positive peritoneal cytology does not alter the stage according to the FIGO 2009 system, it should be considered a poor prognostic sign. The high proportion of nonendometrioid carcinomas in the stage IIIC2 category may reflect different patterns of retroperitoneal spread among tumors with different histologic subtypes.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 99%

FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The definition of stage II endometrial cancer was changed in the most recent FIGO 2009 staging system; tumours with endocervical glandular involvement (previously stage IIA) were moved to stage I as this has no prognostic impact 142,143. As a result, stage II now only includes tumours with cervical stromal invasion 144…”

Section: Adjuvant Treatmentmentioning

confidence: 99%

“…142,143 As a result, stage II now only includes tumours with cervical stromal invasion. 144 Stage II tumours have been associated with an increased frequency of deep myometrial invasion and grade 3 histology, making it difficult to conclude if cervical invasion alone is the reason for the observed higher risk of recurrence and lower OS compared with stage I disease.…”

Section: High-risk Stage II Endometrial Cancermentioning

confidence: 99%

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up

Colombo

Creutzberg

Amant³

et al. 2016

Int J Gynecol Cancer

601

569

View full text Add to dashboard Cite

show abstract

“…This zonation is not observed in any case of atypical polypoid adenomyomas or endometrial polyps. 24 Myometrial or vascular invasion is not a prerequisite for diagnosis.…”

Section: Low-grade Müllerian Adenosarcomamentioning

confidence: 99%

Small biopsy pathology of mass lesions of the endometrial cavity: differential diagnostic considerations

Liptak

Barnetson

2014

Southern African Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Sampling for histological examination is usually part of the work-up for further planning with regard to the management of patients presenting with uterine bleeding. This review, utilising the classification of the World Health Organization, aims to discuss some commonly recurring differential diagnostic problems on small biopsy specimens. Diagnostic difficulties generally relate to representativeness of the sample, determining the site of the lesion, and fragmentation and trauma artefact. Reference is made to clinical relevance, and attention drawn to some lesser known diagnostic entities. Morphological features and immunohistochemical markers that are useful in certain differential diagnostic scenarios are highlighted. The level of diagnostic certainty should be indicated in the report, and when the limitations do not permit a definite diagnosis in a small sample, the pathologist should provide the clinician with a differential diagnosis on which further management decisions can be based. P Peer reviewed.

show abstract

Does the FIGO 2009 Endometrial Cancer Staging System More Accurately Correlate With Clinical Outcome in Different Histologies?

Cited by 25 publications

References 22 publications

FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype

FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up

Small biopsy pathology of mass lesions of the endometrial cavity: differential diagnostic considerations

Contact Info

Product

Resources

About